Literature DB >> 20061651

Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment.

Mark A Smith1, Xiongwei Zhu, Massimo Tabaton, Gang Liu, Daniel W McKeel, Mark L Cohen, Xinglong Wang, Sandra L Siedlak, Barney E Dwyer, Takaaki Hayashi, Masao Nakamura, Akihiko Nunomura, George Perry.   

Abstract

It is now established that oxidative stress is one of the earliest, if not the earliest, change that occurs in the pathogenesis of Alzheimer's disease (AD). Consistent with this, mild cognitive impairment (MCI), the clinical precursor of AD, is also characterized by elevations in oxidative stress. Since such stress does not operate in vacuo, in this study we sought to determine whether redox-active iron, a potent source of free radicals, was elevated in MCI and preclinical AD as compared to cognitively-intact age-matched control patients. Increased iron was found at the highest levels both in the cortex and cerebellum from the pre-clinical AD/MCI cases. Interestingly, glial accumulations of redox-active iron in the cerebellum were also evident in preclinical AD patients and tended to increase as patients became progressively cognitively impaired. Our findings suggests that an imbalance in iron homeostasis is a precursor to the neurodegenerative processes leading to AD and that iron imbalance is not necessarily unique to affected regions. In fact, an understanding of iron deposition in other regions of the brain may provide insights into neuroprotective strategies. Iron deposition at the preclinical stage of AD may be useful as a diagnostic tool, using iron imaging methods, as well as a potential therapeutic target, through metal ion chelators.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061651      PMCID: PMC2842004          DOI: 10.3233/JAD-2010-1239

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  86 in total

1.  Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease.

Authors:  M A Smith; G J Petot; G Perry
Journal:  J Alzheimers Dis       Date:  1999-11       Impact factor: 4.472

2.  Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.

Authors:  A McShea; P L Harris; K R Webster; A F Wahl; M A Smith
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

3.  4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.

Authors:  L M Sayre; D A Zelasko; P L Harris; G Perry; R G Salomon; M A Smith
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

Review 4.  Nanoparticle and other metal chelation therapeutics in Alzheimer disease.

Authors:  Gang Liu; Matthew R Garrett; Ping Men; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biochim Biophys Acta       Date:  2005-09-25

5.  Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease.

Authors:  Patrizia Mecocci; M Cristina Polidori; Antonio Cherubini; Tiziana Ingegni; Paola Mattioli; Marco Catani; Patrizia Rinaldi; Roberta Cecchetti; Wilhelm Stahl; Umberto Senin; M Flint Beal
Journal:  Arch Neurol       Date:  2002-05

6.  Absence of cognitive impairment or decline in preclinical Alzheimer's disease.

Authors:  W P Goldman; J L Price; M Storandt; E A Grant; D W McKeel; E H Rubin; J C Morris
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

Review 7.  A metabolic basis for Alzheimer disease.

Authors:  George Perry; Akihiko Nunomura; Arun K Raina; Gjumrakch Aliev; Sandra L Siedlak; Peggy L R Harris; Gemma Casadesus; Robert B Petersen; William Bligh-Glover; Elizabeth Balraj; Grace J Petot; Mark A Smith
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

8.  Oxidative stress increases expression and activity of BACE in NT2 neurons.

Authors:  Elena Tamagno; Paola Bardini; Alessandra Obbili; Antonella Vitali; Roberta Borghi; Damiano Zaccheo; Maria A Pronzato; Oliviero Danni; Mark A Smith; George Perry; Massimo Tabaton
Journal:  Neurobiol Dis       Date:  2002-08       Impact factor: 5.996

Review 9.  Iron: the Redox-active center of oxidative stress in Alzheimer disease.

Authors:  Rudy J Castellani; Paula I Moreira; Gang Liu; Jon Dobson; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  Neurochem Res       Date:  2007-05-17       Impact factor: 3.996

10.  Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease.

Authors:  Sandra L Siedlak; Gemma Casadesus; Kate M Webber; Miguel A Pappolla; Craig S Atwood; Mark A Smith; George Perry
Journal:  Free Radic Res       Date:  2009-02
View more
  133 in total

1.  Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Authors:  Jaya R P Prasanthi; Matthew Schrag; Bhanu Dasari; Gurdeep Marwarha; April Dickson; Wolff M Kirsch; Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  MK-801 effect on regional cerebral oxidative stress rate induced by different duration of global ischemia in gerbils.

Authors:  Vesna Selakovic; Branka Janac; Lidija Radenovic
Journal:  Mol Cell Biochem       Date:  2010-04-27       Impact factor: 3.396

Review 3.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

4.  Early post-natal iron administration induces astroglial response in the brain of adult and aged rats.

Authors:  Liana Lisboa Fernandez; Maria Noêmia Martins de Lima; Felipe Scalco; Gustavo Vedana; Clívia Miwa; Arlete Hilbig; Mônica Vianna; Nadja Schröder
Journal:  Neurotox Res       Date:  2010-12-17       Impact factor: 3.911

5.  Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

Authors:  Hailin Zheng; Moussa B H Youdim; Mati Fridkin
Journal:  ACS Chem Neurosci       Date:  2010-10-04       Impact factor: 4.418

6.  The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons.

Authors:  Akihiko Nunomura; Toshio Tamaoki; Nobutaka Motohashi; Masao Nakamura; Daniel W McKeel; Massimo Tabaton; Hyoung-Gon Lee; Mark A Smith; George Perry; Xiongwei Zhu
Journal:  J Neuropathol Exp Neurol       Date:  2012-03       Impact factor: 3.685

Review 7.  CCSVI and MS: no meaning, no fact.

Authors:  Claudio Baracchini; Matteo Atzori; Paolo Gallo
Journal:  Neurol Sci       Date:  2012-05-09       Impact factor: 3.307

Review 8.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

9.  Calorie restriction down-regulates expression of the iron regulatory hormone hepcidin in normal and D-galactose-induced aging mouse brain.

Authors:  Shougang Wei; Wenli Shi; Man Li; Qian Gao
Journal:  Rejuvenation Res       Date:  2014-02       Impact factor: 4.663

10.  Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.

Authors:  Lana Kupershmidt; Tamar Amit; Orit Bar-Am; Orly Weinreb; Moussa B H Youdim
Journal:  Mol Neurobiol       Date:  2012-07-31       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.